
Ketoconazole Tablets, USP
200 mg
Antifungal therapy — generic prescription medicine.
View label (DailyMed)Bioraza Pharma — a Bioraza Group company
Bioraza Pharmaceuticals is an MHRA-approved, privately owned and one of the fastest-growing pharmaceutical companies in the United Kingdom, engaged in contract development and manufacturing of generic pharmaceuticals.
Our analytical laboratory — quality at every stage
Explore
About Bioraza Pharma
Bioraza Pharmaceuticals is respected for having acquired strong capabilities in developing generic formulations and world-class generic products over the years. We develop niche generic drugs with expertise in advanced scientific research, process development, patent analysis, regulatory compliance and market & competition analysis.
From our London facility we take products from formulation through analytical development, scale-up, regulatory filing and commercial manufacturing — giving partners a single, accountable route to market.
What drives us
Bioraza Pharma strives to revolutionise the pharmaceutical industry by developing groundbreaking treatments that not only enhance health outcomes but also inspire hope among patients and communities.
We equip patients and healthcare providers with the tools and knowledge necessary to navigate serious illnesses confidently and effectively.
Our commitment to innovation reaches over 250 million individuals, reflecting a dedication to global health equity and access to advanced therapeutic solutions.
By reimagining medicine, we foster collaboration among researchers, manufacturers and policymakers to tackle the complexities of serious diseases collectively.
Capabilities
One partner from molecule to market — development, manufacturing, analytics and regulatory support.
Our products
Generic prescription medicines developed and manufactured by Bioraza Pharma.

200 mg
Antifungal therapy — generic prescription medicine.
View label (DailyMed)
5 mg
Schedule II controlled substance — prescription only.
View label (DailyMed)
10 mg
Schedule II controlled substance — prescription only.
View label (DailyMed)200 mg
Disease-modifying antirheumatic therapy — prescription only.
View label (DailyMed)Global presence
Our pharmaceutical teams work from the group head office in London, supported by offices in New Mexico, Dubai and Lisbon.
Head officeGroup headquarters
Europe — Head Office
The WestWorks, 181 Wood Ln,
London W12 7FQ, United Kingdom

North American operations
North America
New Mexico, United States
Serving partners across the Americas

Regional office
Asia & Middle East
Dubai, United Arab Emirates
Serving partners across Asia & the Gulf

Continental Europe office
Europe — Continental
Lisbon, Portugal
Serving partners across continental Europe
Talk to us
Our business development team will respond within one working day.